Loading stock data…
Xencor, Inc. (XNCR)
$15.60+0.55 (+3.65%)
Market ClosedLast close Jun 29
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xencor, Inc. in the Healthcare sector is trading at $15.60 with a market capitalization of $1.1B. Wall Street consensus targets $28.50 (12 analysts), implying a +82.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $18.69, remaining 19.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +82.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.52M↓ | $28.24M↑ | $21.00M↓ | $43.61M↑ | $32.73M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$77.86M↓ | -$53.63M↓ | -$47.52M↓ | -$33.17M↑ | -$43.18M |
| Net Income | -$128.92M↓ | -$6.65M↓ | -$6.03M↑ | -$30.82M↑ | -$48.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.44%
Volume
Today's trading volume
749,202
Recent News
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
Xencor’s latest research update includes a US$1 increase in the stock’s price target, while the model’s fair value anchor of US$28.50 stays in place. Bullish analysts view this higher target as a sign that updated work still supports upside potential, even as more cautious voices highlight limited near term catalysts and execution risk around the pipeline. As you read on, you will see how to track these shifting views and what they might mean for your own Xencor watchlist. Stay updated as the...
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded...
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting XmAb412, a bispecific antibody designed to inhibit both TL1A and IL-23p19. Charles Liles, Xencor’s head o
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?